*Sponsored
Going Green Early, NYSE American Profile (NNVC) Has Pushed Above 4 Key Technical Chart Levels
February 5th Greetings, Friend!
Do you have NanoViricides, Inc. (NYSE American: NNVC) on your watchlist this morning?
In case you're missing it, NNVC is off to a solid green start early Wednesday and it may be the beginning.
With today's green burst, NNVC has found itself above 4 key chart technical levels after the opening bell. They include NNVC's:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Don't forget. This is a low float idea with fewer than 14Mn shares which means volatility potential could be explosive.
Take a quick moment to review my initial report below and consider (NYSE American: NNVC) for your watchlist. -----
Breaking...
We've identified a new breakout idea currently on the NYSE American.
So, what's special about this one? This is a low float idea.
Registering fewer than 14Mn shares in its float, volatility potential could be extremely present.
Could that be part of the reason as to why this profile was able to complete a 250% move during the past 12 month period?
With an aim to disrupt multiple, Bn dollar markets, this company has eluded Wall Street's attention for the time being.
But for how much longer, that's tough to say.
As this company powers forward in 2025 and beyond, it may just be a matter of time until they become a household name as global health uncertainties could propel their game-changing work into the spotlight.
Hitting #1 on my watchlist this week, it may be time to consider this breakout idea for your radar: NanoViricides, Inc. (NYSE American: NNVC).
NanoViricides, Inc. is a global leader in the development of nanomedicine drugs.
Their unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against vir-uses.
A nanoviricide is designed to specifically attack enveloped vir-us particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do.
It can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.
The company's unique biomimetic approach enables creation of drugs that a vir-us would be highly unlikely to escape due to mutations.
NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product.
This facility is fully owned by the Company with no mortgage and is a major asset.
This flexible, multi-product pilot plant can supply drug product for all of their programs through human clinical trials.
Their cGMP manufacturing ability enables substantial time and cost savings in their drug development programs.
Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100Mn~$500Mn per year.
Company Sources: Presentation. Website. |
No comments:
Post a Comment